Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRuE-AD4: Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817Phase 3Completed
- Sponsor
- Incyte
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Ruxolitinib 1.5% Cream BID with Vehicle Cream BID (2 arms). Primary endpoints: Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score at 8 weeks and Percentage of Participants With Investigator's Global Assessment Treatment Success at 8 weeks. Started Apr 2024; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06238817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238817.